| Rituxan (rituximab) / Roche |
RiVa, NCT03307746: A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma |
|
|
| Active, not recruiting | 2a | 26 | Europe | Varlilumab, Rituximab | University Hospital Southampton NHS Foundation Trust, University Hospital Plymouth NHS Trust, The Christie NHS Foundation Trust, Oxford University Hospitals NHS Trust, Celldex Therapeutics, Cancer Research UK | B Cell Lymphoma | 02/21 | 03/24 | | |
ACTRN12606000495527: Abbreviated Course Rituximab for Auto-immune Disease Refractory to Standard Immunosuppressive Therapy |
|
|
| Not yet recruiting | 2 | 30 | | | Melbourne Health - The Royal Melbourne Hospital, Pharmaceutical industry grant | Auto-immune disorders | | | | |
ACTRN12605000236695: Phase II single centre study assessing the efficacy and safety of I-131 rituximab radioimmunotherapy of relapsed or refractory diffuse large B cell lymphoma. |
|
|
| Not yet recruiting | 2 | 40 | | | Fremantle Hospital & Health Service, Fremantle Hospital & Health Service, Roche | Diffuse large B cell lymphoma | | | | |
ACTRN12621001529831p: NHL35: A study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for patients with primary mediastinal B-Cell lymphoma. |
|
|
| Not yet recruiting | 2 | 43 | | | Australasian Lymphoma and Leukaemia Group, Australasian Leukaemia and Lymphoma Group | Primary mediastinal B-cell lymphoma | | | | |
ACTRN12623000640606: CLL08 - A study to evaluate the efficacy of venetoclax/rituximab (VenR) re-treatment in relapsed/refractory Chronic Lymphocytic Leukaemia (CLL) patients with disease progression following VenR as their last line of therapy. |
|
|
| Not yet recruiting | 2 | 80 | | | Australasian Leukaemia and Lymphoma Group (ALLG), Australasian Leukaemia and Lymphoma Group (ALLG) | Chronic Lymphocytic Leukaemia | | | | |
| Recruiting | 2 | 10 | | | St Vincent's Hospital / University of New South Wales, Roche Product, St Vincent's Hospital | Sjogrens Syndrome | | | | |
ACTRN12607000628448: A pilot study of combining rituximab and low-dose (1.0Gy) total nodal irradiation in treatment of extensive chronic graft-versus-host disease |
|
|
| Recruiting | 2 | 20 | | | Simon He and Andrew Grigg, Roche Products Pty Ltd | Chronic graft-versus-host disease (GVHD) | | | | |
ACTRN12612000591853: The R- 100 ITP Study : evaluating the efficacy of a single weekly dose of 100mg of Rituximab over 4 weeks in patients with refractory or relapsing idiopathic thrombocytopaenic purpura |
|
|
| Recruiting | 2 | 50 | | | Florence Peterson Fund, Florence Peterson Fund | Idiopathic thrombocytopaenic purpura | | | | |
ACTRN12607000153415: INTIAL STUDY - Indolent Non-Hodgkin's ImmunoradioTherapy Initiated Approach in Lymphoma |
|
|
| Recruiting | 2 | 100 | | | Fremantle Hospital, Fremantle Hospital and Health Service | Advanced stage follicular and low-grade non-Hodgkin's lymphoma | | | | |
ACTRN12608000554369: A Study of Apomab in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy |
|
|
| Active, not recruiting | 2 | 50 | | | Genentech, Inc, Genentech, Inc | Non-Hodgkin's Lymphoma (NHL) | | | | |
jRCTs041210104: Multicenter clinical trial to evaluate the efficacy of rituximab combination chemotherapy for children or AYAswith localized mature B-cell lymphoma |
|
|
| Recruiting | 2 | 100 | Japan | Rituxan (rituximab) - Roche, cyclophosphamide - Generic mfg., vincristine - Generic mfg. | National Hospital Organization Nagoya Medical Center | Mature B-cell lymphoma | | | | |
ACTRN12621001529831: NHL35: A study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for patients with primary mediastinal B-Cell lymphoma. |
|
|
| Recruiting | 2 | 35 | | | Australasian Lymphoma and Leukaemia Group, Australasian Leukaemia and Lymphoma Group | Primary mediastinal B-cell lymphoma | | | | |
| Completed | 2 | 137 | | Hi-chop ;R-chop | Cancer center of Sun Yat-Sen University; Zhejiang Hisun Pharmaceutical Co., Ltd, Zhejiang Hisun Pharmaceutical Co., Ltd | Diffuse large B-cell lymphoma | | | | |
ChiCTR2100054451: Phase II clinical study of tislelizumab combined with R-CHOP in the first-line treatment of unspecified EBV-positive diffuse large B-cell lymphoma |
|
|
| Recruiting | 2 | 26 | China | Tislelizumab combined with R-CHOP | Fudan University Cancer Hospital ; Fudan University Cancer Hospital, BeiGene | EBV-positive diffuse large B-cell lymphoma (EBV+ DLBCL) | | | | |
2004-004349-16: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high dose BEAM followed by autologous stem cell transplantation (ASCT) |
|
|
| Ongoing | 2 | 75 | Europe | Ibritumomab tiuxetan, Yttrium-90, CARMUSTINE, Mabthera, Aracytine, Alkeran, Etoposide, Ro45 2994, Kit for radiopharmaceutical preparation, Radiopharmaceutical precursor, Powder and solvent for solution for injection, Concentrate for solution for infusion, Powder and solvent for solution for infusion, Solution for infusion, Zevalin, Ytracis, BCNU, Mabthera100mg, Mabthera500mg, Aracytine, Alkeran, VP16 | GELA Group | Low grade B-cell lymphoma CD20 positive:-Marginal zone-Lymphocytic-Follicular | | | | |
2006-003836-31: A protocol based treatment for early and severe systemic sclerosis with (anti-CD-20) rituximab |
|
|
| Ongoing | 2 | 20 | Europe | Rituximab, Concentrate for solution for infusion, MabThera | University Hospital Gent | systemic sclerosis | | | | |
2009-012034-70: A protocol based treatment for debilitating fibrosing skin disorders with (anti-CD-20), rituximab |
|
|
| Ongoing | 2 | 10 | Europe | Rituximab, Concentrate for solution for infusion, Mabthera | University Hospital Ghent | Fibrosing skin disorders | | | | |
NCT00261651: Phase II Study for Patients With Relapsed Primary Central Nervous System Lymphoma |
|
|
| Active, not recruiting | 2 | 3 | US | rituximab, Rituxan, carboplatin, Other Names:, Paraplatin®, CBDCA, cyclophosphamide, Cytoxan, etoposide phosphate, Etopophos, cytarabine, ARA-C | Ohio State University Comprehensive Cancer Center | Lymphoma | 12/09 | 12/11 | | |
2010-018794-38: EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) |
|
|
| Ongoing | 2 | 30 | Europe | Concentrate for solution for injection, MABTHERA | FONDAZIONE IRCCS CA, GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO | THROMBOTIC THROMBOCYTOPENIC PURPURA | | | | |
2009-015968-34: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial |
|
|
| Ongoing | 2 | 80 | Europe | Rituximab, EU/1/98/067/001, Intravenous infusion, Rituximab | FRED HUTCHINSON CANCER RESEARCH CENTER | Chronic lymphocytic leukemia (CLL) is a malignant disease. CLL is the most common form of leukemia in western countries. Median age at diagnosis is 70 years, and only 10-15% of patients are younger than 50 years. Despite some therapeutic progress, standard treatment is not curative for CLL | | | | |
2009-012432-32: Et randomiseret fase ll studie af primær kemoterapi med højdosis Methotrexat og højdosis Cytarabin med eller uden thiotepa og med eller uden Rituximab efterfulgt af strålebehandling eller højdosis kemoterapi med autolog stamcelletransplantation hos immunkompetente patienter med nydiagnosticeret primært CNS-lymfom. |
|
|
| Ongoing | 2 | 200 | Europe, RoW | Methotrexate, Cytarabine, Rituximab, Thiotepa, Carmustine, Solution for injection, Concentrate for solution for infusion, Powder for injection, Powder and solvent for solution for infusion, Methotrexate, Cytarabine, Mabthera, Thiotepa, Carmustine | IELSG-International Extranodal Lymphoma Study Group, University Medical Center Freiburg Dept. Klinikum Stuttgart, Stuttgart Cancer Center, University Hospital Southampton NHS Foundation Trust, International Extranodal Lymphoma Srudy Group IELSG | Newly diagnosed Primary CNS Lymphoma, Diseases [C] - Cancer [C04] | | | | |
NCT00060164: Rituximab, Autologous Vaccine Therapy, and Sargramostim in Treating Patients With Recurrent or Refractory Follicular B-Cell Lymphoma |
|
|
| Active, not recruiting | 2 | | US | autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim | University Hospitals Seidman Cancer Center, National Cancer Institute (NCI) | Lymphoma | | | | |
2011-001534-42: Clinical study in which are enrolled patients with malignant hematologic diseases for which there is no indication for allogeneic bone marrow transplantation, and for whom a suitable donor has been identified (fully compatible or partially compatible). Studio clinico nel quale vengono arruolati pazienti affetti da malattie ematologiche maligne, per i quali ci sia indicazione a trapianto di midollo osseo allogenico, e per i quali sia stato individuato un donatore idoneo (totalmente compatibile o parzialmente compatibile). |
|
|
| Ongoing | 2 | 154 | Europe | Powder for solution for infusion, Solution for infusion, Tablet, Coated tablet, FLUDARA*EV 5FL 50MG, OVASTAT, ATG FRESENIUS S, MABTHERA*EV 1FL 50ML 500MG, RAPAMUNE*30CPR RIV 2MG, MYFORTIC*250CPR RIV 360MG | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR, MEDAC, FRESENIUS BIOTECH | Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched family is from the register. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da patologie maligne ematologiche (leucemia, mieloma, linfoma), candidati a trapianto allogenico da donatore HLA-identico o HLA- mismatched sia familiare che da registro., Pediatric and adult patients (aged 1 to 70 years) suffering from blood cancer (leukemia, lymphoma, etc..) to be undergoing bone marrow transplantation. Pazienti pediatrici e adulti (età compresa da 1 a 70 anni) affetti da tumori del sangue (leucemie, linfomi etc.) che dovranno essere sottoposti a trapianto di midollo osseo., Diseases [C] - Immune System Diseases [C20] | | | | |
2012-001597-29: Tumor uptake of ofatumumab and rituximab, labeled with 89Zirconium, in patients with malignant lymphoma. Tumor opname van ofatumumab en rituximab, gelabeld met 89Zirconium bij patienten met lymfeklierkanker |
|
|
| Ongoing | 2 | 45 | Europe | rituximab-N-succinyl-desferal-zirconium-89, ofatumumab-N-succinyl-desferal-zirconium-89, 89Zr-rituximab, 89Zr-ofatumumab, Solution for injection/infusion | VU University Medical Center, VU University Medical Center, GlaxoSmithKline | Diffuse large B cell lymphoma (DLBCL), lymphoma, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT00059956: Immunotherapy Combined With Chemotherapy Followed by Radiation Therapy and Chemotherapy in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma |
|
|
| Active, not recruiting | 2 | | US | rituximab, cytarabine, methotrexate, procarbazine hydrochloride, vincristine sulfate, radiation therapy | Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI) | Lymphoma | | | | |
UPCC 02408, NCT00783367: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas |
|
|
| Completed | 2 | 50 | US | Lenalidomide, Revlimid (lenalidomide), Dexamethasone, Decadron (dexamethasone), Rituximab, Rituxan (rituximab) | Abramson Cancer Center at Penn Medicine | Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma | 11/12 | 11/20 | | |
|
NCT01534767: Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant |
|
|
| Recruiting | 2 | 19 | US | sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, laboratory biomarker analysis, flow cytometry | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Hairy Cell Leukemia, Waldenstrom Macroglobulinemia | 06/13 | 10/13 | | |
2012-004955-35: A single-center randomized double-blind placebo-controlled trial “Treatment of Systemic Sclerosis with Rituximab: evaluation of the effectiveness of B-cell depletion therapy” |
|
|
| Ongoing | 2 | 16 | Europe | Powder for infusion, Mabthera | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI, UNIVERSITA' CATTOLICA | SYSTEMIC SCLEROSIS, SYSTEMIC SCLEROSIS, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT00524628: Rituximab and Pegfilgrastim in Treating Patients With Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 40 | US | pegfilgrastim, rituximab, flow cytometry, immunohistochemistry staining method | Roswell Park Cancer Institute | Lymphoma | 09/13 | | | |
CALGB-50403, NCT00310037: Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 151 | US | bortezomib | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Millennium Pharmaceuticals, Inc. | Mantle Cell Lymphoma | 12/13 | | | |
|
NCT01472562: Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma |
|
|
| Completed | 2 | 38 | US | lenalidomide, revlimid, rituximab, rituxan | Weill Medical College of Cornell University, Celgene | Mantle Cell Lymphoma | 04/14 | 07/23 | | |
|
| Terminated | 2 | 154 | Europe | Rituximab, Rituximab (MabThera), lenalidomide, Lenalidomide (Revlimid) | Swiss Group for Clinical Cancer Research | Lymphoma | 06/14 | 01/23 | | |
|
2014-001532-11: ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA |
|
|
| Ongoing | 2 | 10 | Europe | ARENEGYR, Ngr-TNF, Solution for injection | Ospedale San Raffaele, Ospedale San Raffaele | Primary non-Hodgkin lymphoma in the central nervous system relapse / refractory Linfoma non Hodgkin primitivo del Sistema nervoso centrale in ricaduta/refrattario, cancer of the lymphocytes localized exclusively at the level of the central nervous system unresponsive or relapsed after at least one line of therapy tumore dei linfociti localizzato esclusivamente a livello del sistema nervoso centrale non responsivo o ricaduto dopo almeno una linea di terapia, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2014-003046-27: STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF VEMURAFENIB (ZELBORAF) IN COMBINATION WITH MONOCLONAL ANTIBODY RITUXIMAB (MABTHERA) IN PREVIOUSLY TREATED PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION |
|
|
| Ongoing | 2 | 10 | Europe | vemurafenib, Rituximab, Film-coated tablet, Solution for infusion, ZELBORAF, MabThera | Dipartimento di Medicina, Dipartimento di Medicina Università di Perugia | HAIRY CELL LEUKEMIA (HCL) CARRYING THE BRAF-V600E MUTATION, B lymphocytes cancer, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2014-001620-29: Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy. Ensayo clínico para evaluar el tratamiento con un medicamento (lenalidomida) añadido a la quimioterapia utilizada habitualmente en pacientes con linfoma difuso de células grandes B (cáncer de la sangre) que no han respondido bien a tratamientos previos y que no pueden recibir quimioterapia a altas dosis |
|
|
| Ongoing | 2 | 77 | Europe | Lenalidomide, Rituximab, Gemcitabine, Cisplatin, NA, Capsule, hard, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Revlimid 5 mg, MabThera, Revlimid 10 mg, Revlimid 15 mg | Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL), Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL) | Refractory Diffuse large B-cell lymphoma. Linfoma difuso de células grandes B refractarios., Sort of cancer (Large B cells lymphoma) from specific haematological cells (from the blood). Tipo de cáncer (Linfoma de cálulas B grandes) que afecta a determinadas células hematológicas (de la sangre), Diseases [C] - Cancer [C04] | | | | |
2013-004635-69: A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphoma Obinutuzumab monotherapie voor rituximab-refractair folliculair lymfoom |
|
|
| Ongoing | 2 | 25 | Europe | obinutuzumab, obinutuzumab-N-succinyl-desferal-zirconium-89, RO5072759, 89Zr-obinutuzumab, Concentrate for solution for infusion, Solution for injection/infusion | VU University Medical Center, VU University Medical Center, Roche Nederland B.V. | rituximab refractory follicular lymphoma, rituximab refractory follicular lymphoma, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
SWOG-C10404, NCT00602459: Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia |
|
|
| Completed | 2 | 418 | Canada, US | Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima | National Cancer Institute (NCI), Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, SWOG Cancer Research Network | Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia | 12/14 | 04/23 | | |
2014-003031-19: This is a study to valuate the activity and feasibility of a new sequential chemoimmunotherapy program in patients with Diffuse Large B Cell Lymphoma and central nervous system involvement at diagnosis or relapse. |
|
|
| Ongoing | 2 | 76 | Europe | METROTREXATO, RITUXIMAB, CITARABINA, IFOSFAMIDE, CARBOPLATINO, ETOPOSIDE, TIOTEPA, BCNU, cytarabine liposome intrathecal, Solution for injection, Concentrate for solution for infusion, Injection, Solution for infusion, Powder for solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Suspension for injection, methotrexate, Cytarabine, rituximab, Etoposide, carboplastin, hydrocortisone | IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP), International Extranodal Lymphoma Study Group, IELSG, Erasmus MC, NKI-AVL, LUMC | systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT01199575: Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
|
|
| Completed | 2 | 30 | US | Revlimid, lenalidomide, Rituximab, Rituxan | University of California, San Diego, Celgene Corporation | Chronic Lymphocytic Leukemia, CLL | 01/15 | 02/22 | | |
NCT01661881: Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 23 | US | Rituximab, Rituxan, Bendamustine, Treanda, Cytarabine, Depocyt | Dana-Farber Cancer Institute, Massachusetts General Hospital | Mantle Cell Lymphoma | 02/15 | 03/25 | | |
|
2014-005069-60: R-CPOP (Rituximab plus Cyclophosphamid, Pixantron, Vincristin, Prednison) as first line therapy for elderly patients with diffuse-large B cell lymphoma (DLBCL) and for patients with limited cardiac function with DLBCL R-CPOP (Rituximab plus Cyclophosphamid, Pixantron, Vincristin, Prednison) als Erstlinientherapie für ältere Patienten mit diffus großzelligem B-Zell-Lymphom (DLBCL) und für Patienten mit eingeschränkter Herzfunktion mit DLBCL |
|
|
| Ongoing | 2 | 60 | Europe | Powder for concentrate for solution for infusion, Pixuvri® | Medical Center - University of Freiburg, Servier Affaires Médicales, CTI Life Sciences Limited | Diffuse-large B cell lymphoma (DLBCL), A subtype of non-Hodgkin lymphoma, a tumour disease involving B lymphocytes, a particular type of white blood cells with a key role in immune system, Diseases [C] - Cancer [C04] | | | | |
2015-000056-23: A new kind of scan for patients with a lymphoma in the central nervous system |
|
|
| Ongoing | 2 | 10 | Europe | 89Zirkonium-rituximab, Solution for injection | UMC Utrecht, UMC Utrecht | central nervous system localized malignant lymphoma., lymphoma in the brain, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2005-001569-33: First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC) |
|
|
| Ongoing | 2 | 60 | Europe | MabTheta, Ro 45-2294, MabThera®, MabThera® | Dept. Hematology, Hospital Clinic | Patients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treated | | | | |
2005-002274-30: A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. |
|
|
| Ongoing | 2 | 40 | Europe | MabThera, IDEC-C2B8, Ro 45-2294, MabThera, MabThera | University College London | Thrombotic Thrombocytopenia Purpura | | | | |
2006-003243-23: A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma |
|
|
| Ongoing | 2 | 45 | Europe | GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG, GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE \"G. PASCALE\" | Patients with Relapsed and Primary Refractory Lymphoma | | | | |
2005-005358-27: Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study |
|
|
| Ongoing | 2 | 10 | Europe | MabThera 500, MabThera 500 | University Hospital of North Staffordshire | Ankylosing spondylitis (AS) is an inflammatory condition primarily affecting the spine. The disease may remain symptomatic and progressive life-long. It is part of the family of spondyloarthropathies which also comprises psoriatic arthritis, reactive arthritis and enteropathic arthritis. | | | | |
2006-002141-37: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation |
|
|
| Ongoing | 2 | 32 | Europe | dexamethasone, cisplatin, cytarabine, Mabthera, Mabthera | HOVON foundation | relapsed B cell lymphoma | | | | |
2006-004851-39: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDYTO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENTTREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN)IN ELDERLY ( 60 YEARS) PATIENTS WITH DIFFUSE LARGE BCELLLYMPHOMA AFTER 4 CYCLES OF CHOP21 ﾖRITUXIMAB(CHOP21-R) THERAPY. |
|
|
| Ongoing | 2 | 55 | Europe | ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | DIFFUSE LARGE BCELLLYMPHOMA | | | | |
2006-004850-26: A phase II, open-label, prospective, multicenter study to evaluate theefficacy and safety of subsequent treatment with the Zevalin(ibritumomab tiuxetan) study in patients with follicular grade I-IIlymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab(FMR) therapy. |
|
|
| Ongoing | 2 | 55 | Europe | ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | follicular grade I-IIlymphoma | | | | |
2006-006099-39: Anti-CD20 antitest alkalmazása súlyos, hagyományos kezelésekre nem reagáló endokrin orbitopátiában |
|
|
| Ongoing | 2 | 5 | Europe | Rituximab, Mabthera, Mabthera | Department of Endocrinology University of Debrecen Medical and Health Science Center | Endocrin ophthalmopathy (conventional therapy resistent). | | | | |
2005-003796-20: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (\"Zevalin\") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77) |
|
|
| Ongoing | 2 | 12 | Europe | Mabthera, Zevalin, Mabthera, Zevalin | HOVON Foundation | patients with diffuse Large B-Cell lymphoma, CD20-positive | | | | |
2006-005011-10: LOW DOSE RITUXIMAB IN THE TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA. |
|
|
| Ongoing | 2 | 20 | Europe | MABTHERA, MABTHERA | UNIVERSITA DEGLI STUDI DI UDINE | PATIENTS WITH AUTOIMMUNE THROMBOCYTOPENIA. | | | | |
2006-004768-30: Traitement de première ligne des lymphomes du manteau de patients agés de 65 à 80 ans. Evaluation de l\'efficacité, de la toxicité et de facteurs pronostiques moléculaires de l\'inhibiteur du protéasome ( PS341-Velcade) associé à une chimiothérapie et une immunothérapie par rituximab ( schéma RiPAD + C) |
|
|
| Ongoing | 2 | 39 | Europe | VELCADE, PS341, 26866138-AAA-PB-001, VELCADE, VELCADE | GOELAMS | Patient porteur d\'un lymphome du manteau au diagnostic entre 60 et 80 ans | | | | |
2006-000454-44: Etude prospective multicentrique de phase II évaluant l’adjonction du rituximab et du DepoCyte® en intrathécal au protocole de chimiothérapie C5R chez les patients âgés de 18 à 60 ans porteurs de lymphomes non hodgkiniens cérébraux primitifs et de lymphomes systémiques diffus à grandes cellules B avec envahissement neuro-méningé au diagnostic. |
|
|
| Ongoing | 2 | 99 | Europe | DepoCyte, Vincristine, Methotrexate, Adriamycine, Acide Folique, Cyclophosphamide, Prednisolone, Cytarabine, R0452994, DepoCyte, Mabthera, Vincristine, Methotrexate, Adriamycine, Acide Folique, Cyclophosphamide, Prednisolone, Cytarabine, DepoCyte, Mabthera, Vincristine, Methotrexate, Adriamycine, Acide Folique, Cyclophosphamide, Prednisolone, Cytarabine | Groupe d’Etude des Lymphomes de l’Adulte (GELA), The lymphoma Study Association (LYSA), , ROCHE SAS, Napp Pharmaceuticals research Limited | Patiens with primary cerebral or oculocerebral NHL not previously treated with chemotherapy or radiotherapy and diffuse large B-cell lymphomas, with cerebral and / or neuromeningeal involvement at diagnosis | | | | |
2007-000699-18: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI |
|
|
| Ongoing | 2 | 222 | Europe | PREDNISONE, RITUXIMAB, DOXORUBICINE, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, METHOTREXATE, G-CSF, VINCRISTINE, IFOSFAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, MELPHALAN, autologous stem cells, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN | Hospices Civils de Lyon, Groupe d\'Etude des Lymphomes de l\'Adulte(GELA) | CD20+ diffuse large B-cell lymphoma | | | | |
2007-001604-20: A PROSPECTIVE RANDOMIZED STUDY ON THE EFFICACY AND SAFETY OF THE PROPHYLACTIC USE OF RITUXIMAB, ADDED TO STANDARD IMMUNOSUPPRESSIVE TREATMENT IN COMPARISON WITH STANDARD IMMUNOSUPPRESSIVE TREATMENT ALONE IN RENAL TRANSPLANTATION |
|
|
| Ongoing | 2 | 280 | Europe | MabThera, MabThera | Radboud University Nijmegen Medical Center | prophylaxis of acute rejection after renal transplantation | | | | |
2007-005711-26: An open prospective, monocenter, consecutive non randomized clinical trial on therapy with monoclonal antibodies anti-CD20 in the treatment of pemphigus vulgare or foliaceus, serious and resistant to common therapies |
|
|
| Ongoing | 2 | 20 | Europe | MABTHERA, MABTHERA | ISTITUTO DERMOPATICO IMMACOLATA | Pemphigus vulgaris, pemphigus foliaceus | | | | |
2007-005477-54: Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies Condizionamento a base di Treosulfano e profilassi della GvHD con Rapamicina, nel trapianto allogenico non manipolato da donatori alternativi per la cura di patologie neoplastiche ematologiche. |
|
|
| Ongoing | 2 | 85 | Europe | FLUDARA, CELLCEPT, MABTHERA, RAPAMUNE, OVASTAT, ATG FRESENIUS S, FLUDARA, CELLCEPT, MABTHERA, RAPAMUNE, OVASTAT, ATG FRESENIUS S | OSPEDALE S. RAFFAELE DI MILANO | neoplastic and haematologic patologies patologie neoplastiche ed ematologiche | | | | |
2006-006999-38: HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) SUPPORTED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC B-CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OR RELAPSE |
|
|
| Ongoing | 2 | 25 | Europe | MABTHERA, METHOTREXATE, ENDOXAN BAXTER, ETOPOSIDE TEVA, DEPOCYTE, MABTHERA, METHOTREXATE, ENDOXAN BAXTER, ETOPOSIDE TEVA, DEPOCYTE | OSPEDALE S. RAFFAELE | PATIENTS WITH SYSTEMIC B-CELL LYMPHOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS OR RELAPSE | | | | |
2008-000086-38: A PHASE 2, SINGLE ARM, MULTI-CENTER STUDY ON THE BENEFIT/COST/SAFETY PROFILE OF LOW-DOSE RITUXIMAB FOR REFRACTORY MIXED CRYOGLOBULINEMIA |
|
|
| Ongoing | 2 | 52 | Europe | MABTHERA, MABTHERA | AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | Mixed cryoglobulinemia (type II or III) associated with chronic HCV infection (positive serology and/or HCV viremia) | | | | |
2007-002414-19: Etude prospective multicentrique de phase II évaluant la radioimmunothérapie fractionnée avec un anticorps humanisé anti-CD22 marqué à l\'yttrium 90 (90Y-DOTA-hLL2) en consolidation après immuno-chimiothérapie R-CHOP dans les lymphomes B agressifs disséminés du sujet de plus de 60 ans |
|
|
| Ongoing | 2 | 75 | Europe | IgG1 anti-cellule B hLL2 marqué à l\' Ytrium 90, IgG1 anti-celluleB hLL2, 90 Y-DOTA-hLL2, hLL2 IgG, | GOELAMS | lymphomes B agressifs disséminés du sujet de plus de 60 ans et de moins de 80 ans. | | | | |
2006-007083-28: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy. |
|
|
| Ongoing | 2 | 60 | Europe | prednisone, chlorambucil, etoposide, lomustine, 90Y-ibritumomab tiuxetan, A07EA03, Mabthera, Zevalin, Mabthera, Zevalin | HOVON foundation, KWF, Spectrum Pharmaceuticals | Aggressive B-cell NHL | | | | |
2008-004486-26: Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children |
|
|
| Ongoing | 2 | 40 | Europe | MABTHERA, MABTHERA | ISTITUTO GIANNINA GASLINI | Nephrotic Syndrome | | | | |
2007-007545-13: Nytt protokoll för ABO-inkompatibel levertransplantation med Mabthera® och immunadsorption: en pilotstudie. |
|
|
| Ongoing | 2 | 20 | Europe | Mabthera, RO 45-2294/V02, Mabthera, Mabthera | Sahlgrenska Universitetssjukhuset | Patients with liverfailure above 18 years of age, who is submitted to the waiting list for a liver transplantation | | | | |
2008-005687-13: Estudio Fase II abierto prospectivo no aleatorizado para valorar la combinación de rituximab, bendamustina, mitoxantrone, dexametasona (R-BMD) en pacientes con Linfoma Folicular refractarios o en recaída |
|
|
| Ongoing | 2 | 60 | Europe | Bendamustina, RIBOMUSTIN | GELTAMO (Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea) | Linfoma Folicular refractarios o en recaída | | | | |
2008-007180-16: INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMA |
|
|
| Ongoing | 2 | 20 | Europe | Mabthera, Rituximab, Rituximab | LUMC | systemic sclerosis | | | | |
2009-012944-17: Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial. |
|
|
| Ongoing | 2 | 31 | Europe | 90Y-ibritumomab tiuxetan, rituximab, prednisone, cyclophosphamide, vincristine, A07EA03, Zevalin, Mabthera, mabthera, Zevalin, Mabthera, mabthera | VUMC | follicular B cell NHL | | | | |
2009-013422-17: Etude de l’efficacité et de la toxicité d’une stratégie d’allogreffe de cellules souches hématopoïétiques à conditionnement atténué dans le lymphome folliculaire en rechute chimiosensible. |
|
|
| Ongoing | 2 | 33 | Europe | Rituximab, Mabthera, Mabthera | CHU de Bordeaux | Follicular lymphomaAllogeneic hematopoietic stem cell transplantationReduced-intensity conditioning | | | | |
2009-017449-72: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial |
|
|
| Ongoing | 2 | 3 | Europe | MABTHERA, MABTHERA | FRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDREN | Patients with Advanced Chronic Lymphocytic Leukemia | | | | |
2011-001557-85: Intensive induction treatment with B-cell antibody (rituximab), chemotherapy (Ara-C) and steroids (dexamethasone) followed by high dose chemotherapy and autologous transplantation in aggressive mantle cell lymphoma patients younger than 66 years. |
|
|
| | 2 | 15 | Europe | Mabthera, Cytarabine, Dexacortal, Mabthera, Cytarabine, Dexacortal | Nordic Lymphoma Group, Nordic Lymphoma Group | Mantle cell lymphoma | | | | |
| Ongoing | 2 | 30 | Europe | Mabthera Infusion, Solu-Medrone, Synacthen Depot, Rituximab, Methylprednisolone, Tetracosactide acetate, Mabthera infusion, Solu-Medrone, Synacthen Depot, Mabthera infusion, Solu-Medrone, Synacthen Depot | Newcastle upon Tyne Hospitals NHS Foundation Trust, Medical Research Council | Autoimmune Addison\'s disease: autoimmune primary adrenal insufficiency | | | | |
2012-003141-16: A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease. |
|
|
| Ongoing | 2 | 22 | Europe | Etoposide, doxorubicin, Vincristine, Cyclophosphamide, Prednisolon, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisolone, Rituximab, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisolone, Rituximab | VU University Medical Center, VU University Medical Center | Burkitt lymphoma | | | | |
2012-000721-53: An extension trial of intrathecal therapy with monoclonal antibodies in progressive multiple sclerosis ITT-PMS Förlängningsstudie En förlängningsstudie av behandling med monoklonala antikroppar givna direkt i cereborspinalvätskan (\"ryggmärgsvätskan\") vid progressiv multipel skleros |
|
|
| Ongoing | 2 | 30 | Europe | Mabthera, Mabthera, Mabthera | Dept of Neurology, Umeå University Hospital, Umeå, Sweden, Dept of Neurology, Umeå University | Secondary progressive multiple sclerosis | | | | |
2012-004436-36: Effect of rituximab in secondary progressive multiple sclerosis |
|
|
| Ongoing | 2 | 15 | Europe | MabThera, MabThera (Rituximab), MabThera (Rituximab) | Odense University Hospital, Odense University hospital | Multiple Sclerosis | | | | |
NCT01027000: Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Completed | 2 | 68 | US | rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, sirolimus, tacrolimus, allogeneic stem cell transplant | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Genentech, Inc., Biologics, Inc. | Leukemia, Lymphoma | 01/16 | 04/23 | | |
2007-005487-28: Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CLL |
|
|
| Ongoing | 2 | 40 | Europe | dexamethasone, cisplatin, Cytarabine, Mabthera, Mabthera | HOVON Foundation, HOVON, Roche, | Chronic lymphocytic leukemia | | | | |
2010-020659-30: COMBINED THERAPY WITH PEG-INTERFERON-α, RIBAVIRIN AND RITUXIMAB OF HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA |
|
|
| Ongoing | 2 | 66 | Europe | MABTHERA, MABTHERA | AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE | patients anti-HCV, HCV RNA positivity, Na�ve, with cryoglobulinemic vasculitis (detection of serum cryoglobulins associated with purpura, arthralgias and weakness)and with chronic hepatitis | | | | |
PRECIS, NCT00863460: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients |
|
|
| Active, not recruiting | 2 | 140 | Europe | cranial radiotherapy, intensive chemotherapy and hematopoietic stem cell rescue, Thiotepa IV (250 mg/m²/day) day-9 day-8 day-7, Busulfan IV (0.8 mg/kg X 10) day-6 to day-4, Cyclophosphamide IV (60 mg/kg/day) day-3 & day-2, Reinjection of hematopoietic stem cells day0, MTX based chemotherapy, R-RMVP :, Rituximab IV if LNH type B (375 mg/m²) day1, Methotrexate IV (3g/m² during 30 minutes) day1 and day15, Etoposide IV (100 mg/m²) day2, Carmustine IV (100 mg/m²) day3, Prednisone PO (60 mg/m²/day)day1 to day5, R-Aracytine :, Aracytine IV (3g/m²) day1 & day2 | Institut Curie, Ministry of Health, France, Hoffmann-La Roche, Amgen, Pierre Fabre Laboratories | Primary Central Nervous System Lymphoma | 05/16 | 05/26 | | |
2006-003333-33: A randomised controlled, open label, phase II pilot study comparing the toxicity of rituximab plus CHOP chemotherapy with rituximab plus CHOP chemotherapy and bortezomib in adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) being treated in haemato-oncology units within South East Wales |
|
|
| Ongoing | 2 | 60 | Europe | Velcade, Velcade | Cardiff and Vale NHS Trust | Diffuse large B-cell lymphoma | | | | |
| Ongoing | 2 | 15 | Europe | Rituximab, Belimumab, rituximab, Benlysta, rituximab, Benlysta | Leiden University Medical Center, Leiden University Medical Center | Systemic lupus erythematosus | | | | |
2014-002654-39: A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U |
|
|
| Ongoing | 2 | 68 | Europe | Revlimid 2,5 mg, Revlimid 5mg, Revlimid 10 mg, Revlimid 15mg, Revlimid 2,5 mg, Revlimid 5mg, Revlimid 10 mg, Revlimid 15mg | HOVON Foundation, Dutch Cancer Society | MYC positive diffuse large B cell lymphoma and Burkitt lymphoma | | | | |
2016-000209-35: Will a single dose of Rituximab treatment, when taken with anti thyroid drugs for 1 year, stop the over-activity of the thyroid gland from returning once you stop ATD treatment? |
|
|
| Ongoing | 2 | 27 | Europe | Mabthera Infusion, Rituximab, Concentrate for solution for injection/infusion, Mabthera Infusion | Newcastle upon Tyne Hospitals NHS Foundation Trust, Medical Research Council | Graves' hyperthyroidism, An overactive thyroid gland that produces too much thyroid hormone, Diseases [C] - Hormonal diseases [C19] | | | | |
2015-003371-29: Phase II study. A combination of Lenalidomide and Rituximab as front line therapy for elderly frail patients (CGA) with Diffuse Large B-cells non-Hodgkin Lymphoma. Studio di fase II per valutare la combinazione di Lenalidomide e Rituximab in prima linea nei pazienti anziani con linfoma diffuso a grandi cellule B classificati fragili (CGA) |
|
|
| Not yet recruiting | 2 | 68 | Europe | Revlimid 5 mg, Revlimid 10 mg, Revlimid 15 mg, Revlimid 20 mg, [IMP1], [IMP2], [IMP3], [IMP4], Capsule, hard, REVLIMID - 5 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CASPULE, REVLIMID - 10 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 15 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, REVLIMID - 20 MG- CAPSULA RIGIDA- USO ORALE- BLISTER (PCTFE/PVC/ALU)- 21 CAPSULE | FONDAZIONE ITALIANA LINFOMI ONLUS, Celgene | Diffuse Large B-cells non-Hodgkin Lymphoma Linfoma diffuso a grandi cellule B, Elderly frail patients with Diffuse Large B-cells non-Hodgkin Lymphoma. Pazienti anziani con linfoma diffuso a grandi cellule B classificati fragili, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2015-005454-35: An early phase study using a response based combination therapy of rituxumab and ibrutinib in patients with post-transplant lymphoproliferative disorder (PTLD) |
|
|
| Ongoing | 2 | 60 | Europe | Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone, Vincristine, Capsule, hard, Infusion, Oral solution, Imbruvica, MabThera, Myocet, Prednisolone | University of Birmingham, Bloodwise, Janssen | Post-transplant lymphoproliferative disorder, Post-transplant lymphoproliferative disorder, Diseases [C] - Cancer [C04] | | | | |
2016-000118-31: A trial to investigate the efficacy and safety of immunotherapy (intravenous immunoglobulins and rituximab) in patients with antibody-associated psychosis, compared to placebo (SINAPPS2) |
|
|
| Ongoing | 2 | 80 | Europe | IVIG, Rituximab, Solution for infusion, IVIG, Rituximab | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, Medical Research Council | Antibody associated Psychosis, Cases of psychosis that are likely caused by the presence of antibodies that affect the brain, found in the blood., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2014-005015-16: Blood-brain-barrier disruption therapy in primary central nervous system lymphoma BBBD-hoito aivolymfooman hoitona |
|
|
| Ongoing | 2 | 44 | Europe | rituximabi, carboplatin, methotreksate, cyclophosphamide, etoposide, Solution for infusion | Oulu University Hospital, Oulu Univeristy Hospital | Primary centra nervous system lymphoma Primaarinen keskushermostolymfoomna, Brain lymphoma Aivolymfooma, Diseases [C] - Cancer [C04] | | | | |
NCT01516567: Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation |
|
|
| Active, not recruiting | 2 | 47 | Europe, Canada | Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab | Gustave Roussy, Cancer Campus, Grand Paris, Children's Oncology Group | Primary Mediastinal Large B Cell Lymphoma | 04/17 | 12/21 | | |
NCT02093624: A Phase II Trial of Rituximab In Myasthenia Gravis |
|
|
| Not yet recruiting | 2 | 50 | US | Rituximab, Placebo | Yale University | Myasthenia Gravis | 05/17 | 12/17 | | |
2017-000302-37: A study to assess the safety and efficacy of the drugs rituximab and varlilumab in patients with B-cell cancer that did not respond to treatment or has returned. |
|
|
| Not yet recruiting | 2 | 40 | Europe | Varlilumab (as called CDX-1127), Infusion | University Hospital Southampton Foundation Trust | Relapsed or refractory B-Cell malignancies, B-Cell lymphoma in patients who have their disease returning or is resistant to treatment, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 92 | Europe | Gemcitabine, Methylprednisolone, Rituximab, Cisplatin, Lenalidomide | Royal Marsden NHS Foundation Trust, Celgene Corporation | Diffuse Large B-Cell Lymphoma | 02/18 | 08/23 | | |
2017-004628-31: Venetoclax after chemotherapy R-BAC in high-risk elderly patients with mantle cell lymphoma Venetoclax dopo chemioterapia R-BAC in pazienti anziani affetti da linfoma mantellare |
|
|
| Not yet recruiting | 2 | 130 | Europe | Venclyxto, Film-coated tablet, Venclyxto | Fondazione Italiana Linfomi ONLUS, AbbVie S.r.l. | Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Mantle Cell Lymphoma in elderly patients Linfoma mantellare in pazienti anziani, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2017-004532-10: A clinical trial investigating the effect of the drug rituximab on the fertility of women undergoing in vitro fertilization diagnosed with premature ovarian insufficiency due to an autoimmune condition |
|
|
| Ongoing | 2 | 15 | Europe | Concentrate for solution for infusion, Mabthera | Karolinska University Hospital, Vetenskapsrådet (VR) | Autoimmune premature ovarian insufficiency, Premature ovarian insufficiency (POI), Diseases [C] - Hormonal diseases [C19] | | | | |
ChiCTR1900021415: A prospective study of cerebrospinal fluid concentrations of rituximab in primary central nervous system lymphoma |
|
|
| Completed | 2 | 24 | | Induction therapy for PCNSL consisted of six cycles R-MT ;Induction therapy for PCNSL consisted of six cycles R-MT | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, National natural science foundation | Primary central nervous system lymphoma | | | | |
2018-000721-31: A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis. |
|
|
| Not yet recruiting | 2 | 200 | Europe | Mabthera, Infusion, Mabthera | Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital | Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addition, patients will be recruited that has not participated in the RIFUND trial but has been treated with rituximab with the same protocol as in the RIFUND trial as part of clinical practice., Patients with MS included in the trial RIFUND-MS will be offered to continue in this extension trial. Additional patients treated with rituximab as in the RIFUND trial will be recruited., Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-001347-31: Pilot study with rituximab in patients with CIDP not responding to conventional immune therapy Studio pilota con rituximab in pazienti con CIDP non responsivi alla terapia immunologica convenzionale |
|
|
| Ongoing | 2 | 20 | Europe | Rituximab, Solution for infusion, MABTHERA - 1 FIALA 500 MG 50 ML | IRCCS ISTITUTO CLINICO HUMANITAS, Ministero della Salute | Chronic inflammatory demyelinating polyradiculoneuropathy Poliradicoloneuropatia cronica infiammatoria demielinizzante, Chronic inflammatory demyelinating polyradiculoneuropathy Polineuropatia cronica infiammatoria demielinizzante, Diseases [C] - Nervous System Diseases [C10] | | | | |
ACTRN12615000551594: A Phase II Study of Ibrutinib, Rituximab and mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy in very elderly patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
|
|
| Completed | 2 | 80 | | | Australasian Leukaemia and Lymphoma Group, Janssen-Cilag Pty Ltd | elderly DLBCL | | | | |
ChiCTR-OIC-16008700: Rituximab in combination with Abraxane and pegylated liposomal doxorubicin in the treatment of relapsed/refractory diffuse large B cell lymphoma patients who received at least two prior lines of chemotherapy: a mono-center, single arm, phase 2 clinical trial |
|
|
| Not yet recruiting | 2 | 30 | | Rituximab in combination with Abraxane and pegylated liposomal doxorubicin | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Sun Yat-sen University Cancer Center | diffuse large B cell lymphoma | | | | |
2017-004401-40: A trial of CHOP-R therapy with or without acalabrutinib in patients with newly diagnosed Richter's Syndrome |
|
|
| Not yet recruiting | 2 | 105 | Europe | Cyclophosphamide, Acalabrutinib, Doxorubicin, Vincristine, Prednisolone, Rituximab, ACP-196, Powder and solvent for solution for injection/infusion, Capsule, hard, Concentrate and solvent for solution for infusion, Solution for injection, Tablet, Solution for infusion, Cyclophosphamide, Acalabrutinib, Vincristine, Prednisolone, Rituximab | University of Birmingham, Bloodwise, Acerta | Richter's Syndrome, A rare type of non-hodgkin lymphoma, Diseases [C] - Cancer [C04] | | | | |
2017-005137-23: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with (ABC) DLBCLat intermediate-high and high risk Terapia R-CHOP in combinazione con ibrutinib e successivo mantenimento con ibrutinib in pazienti non trattati con linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto. |
|
|
| Not yet recruiting | 2 | 90 | Europe | Ibrutinib, IMP1, Capsule, hard, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (120 CAPSULE RIGIDE) | FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen-Cilag S.p.A | Activated-B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk (IPI =2) Linfoma diffuso a grandi cellule B con profilo ABC (Activated-B-Cell) e rischio intermedio/alto o alto (IPI = 2), B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk Linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2017-000519-18: PIMOC : Personalized targeted therapies in inflammatory complex multi organ disease Personnalisation des traitements de Pathologies Inflammatoires Multi Organes Complexes : PIMOC |
|
|
| Not yet recruiting | 2 | 32 | Europe | SECUKINUMAB, ADALIMUMAB, ANAKINRA, RITUXIMAB, TOCILIZUMAB, USTEKINUMAB, Solution for injection, Solution for infusion | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS | Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. The disease has been resistant to at least two prior lines of treatment. Patient(e) présentant une maladie inflammatoire mal classée, impliquant au moins deux organes dont au moins la peau, et un des suivants : ganglions lymphatiques, système hématopoïétique, articulations, appareil digestif. La maladie a été résistante à au moins deux lignes de traitement., Patients presenting inflammatory non classified disease, resistant to prior treatment patients présentant une maladie inflammatoire non classée, sévère et résistante, Diseases [C] - Immune System Diseases [C20] | | | | |
